Tonsillectomy with uvulopalatopharyngoplasty in obstructive sleep apnea

• Verfasst von: Sommer, Ulrich [VerfasserIn]
• Verfasst von: Herr, Raphael [VerfasserIn]
• Verfasst von: Hörmann, Karl [VerfasserIn]
• Verfasst von: Maurer, Joachim T. [VerfasserIn]
• Titel: Tonsillectomy with uvulopalatopharyngoplasty in obstructive sleep apnea
• Titelzusatz: a two-center randomized controlled trial
• Verf.angabe: J. Ulrich Sommer, Clemens Heiser, Constanze Gahleitner, Raphael M. Herr, Karl Hörmann, Joachim T. Maurer, Boris A. Stuck
• Jahr: 2016
• Umfang: 8 S.
• Fussnoten: Gesehen am 18.01.2019
• Titel Quelle: Enthalten in: Deutsches Ärzteblatt international
• Ort Quelle: Köln : Dt. Ärzte-Verl., 2006
• Jahr Quelle: 2016
• Band/Heft Quelle: 113(2016), 1-2, Seite 1-8
• ISSN Quelle: 1866-0452
• DOI: doi:10.3238/arztebl.2016.0001
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 158639584X

Abstract

Background: Obstructive sleep apnea (OSA) is a very common disorder (prevalence 2-7% in women, 7-14% in men). It impairs the quality of life and increases mortality. Conservative treatment with continuous positive airway pressure is highly effective, but patient compliance is variable. Surgical treatments are controversial, as only a few are supported by evidence from controlled clinical trials. Method: Adult patients with OSA, CPAP intolerance, and oropharyngeal obstruction were included in the trial. All underwent polysomnography (PSG) and were randomly allotted to one of two groups. Patients in the treatment group underwent tonsillectomy with uvulopalatopharyngoplasty (TE-UPPP) within one month. All patients had a follow-up PSG at three months, and all PSGs were evaluated in blinded fashion. The primary outcome variable was the apnea-hypopnea index (AHI) as determined by PSG. Other outcome variables were subjective symptoms (daytime sleepiness, quality of life), complications, and patient satisfaction. Results: 42 patents were included in the trial (23 in the treatment group, 19 in the control group). The baseline AHI was 35.7 ± 19.4/hr in the control group and 33.7 ± 14.6/hr in the treatment group. The corresponding figures at 3 months were 28.6 ± 19.4/hr in the control group and 15.4 ± 14.1/hr in the treatment group (p = 0.036). The intervention also led to significant improvement in daytime sleepiness and in snoring, according to the patients’ and their bed partners’ assessment. 97% of the patients who underwent surgery were satisfied with the outcome. 65% of them needed no further treatment for OSA. Conclusion: TE-UPPP significantly improved apnea/hypopnea, daytime sleepiness, and snoring compared to control (i.e., no) treatment. It is a safe and effective treatment for OSA..